Joel Block to Receptors, Tumor Necrosis Factor
This is a "connection" page, showing publications Joel Block has written about Receptors, Tumor Necrosis Factor.
Connection Strength
0.417
-
Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther. 2013 Jan; 20(1):73-8.
Score: 0.108
-
Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol. 2009 May; 36(5):914-7.
Score: 0.083
-
Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):743-5.
Score: 0.074
-
New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol. 2007 May; 19(3):259-64.
Score: 0.073
-
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002 Feb 16; 359(9306):579-80.
Score: 0.051
-
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Aug 01; 39(3):295-9.
Score: 0.015
-
Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003 Jul-Aug; 21(4):526.
Score: 0.014